

**Speculative**

See key risks on Page 4 and Biotechnology Risk Warning on Page 7. Speculative securities may not be suitable for Retail Clients.

**Analyst**

John Hester 612 8224 2871

**Authorisation**

Elyse Shapiro 613 9235 1877

# Paradigm Biopharmaceuticals (PAR)

## Edging Toward IND

**Recommendation**  
**Buy** (unchanged)  
**Price**  
**\$1.97**  
**Valuation**  
**\$3.00** (previously \$3.15)  
**Risk**  
**Speculative**

**GICS Sector**  
**Pharmaceuticals & Biotechnology**

**Expected Return**

Capital growth	<b>52.3%</b>
Dividend yield	<b>0.0%</b>
Total expected return	<b>52.3%</b>

**Company Data & Ratios**

Enterprise value	<b>\$376.5m</b>
Market cap	<b>\$447.6m</b>
Issued capital	<b>227.2m</b>
Free float	<b>91%</b>
Avg. daily val. (52wk)	<b>\$2.2m</b>
12 month price range	<b>\$1.87 - \$3.19</b>

**Price Performance**

	(1m)	(3m)	(12m)
Price (A\$)	1.94	2.26	3.40
Absolute (%)	14.43	-1.77	-34.71
Rel market (%)	11.79	-8.23	-59.72

**Absolute Price**



SOURCE: IRESS

### Further confirmation on toxicology data

PAR provided an update on its Investigative New Drug (IND) application for Zilosul earlier today. The IND was lodged in March 2021 and following its initial review the FDA had come back to the company with six questions. Today's update indicates the Agency accepted PAR's responses to five of the six questions. The Agency requires further explanation on one final point relating to the non clinical toxicology data.

The key points are: 1) The FDA is placing emphasis on mechanism of action and safety as evidenced by these ongoing enquiries. This drug will potentially be available to millions of users in need of a non-opioid pain relief for osteoarthritis, hence the need for an outstanding safety record; and 2) PAR does not believe it will be required to generate further pre-clinical toxicology data in order to satisfy the FDA's enquiries. The exact nature of the toxicology issue was not discussed, however, we understand the risk can be mitigated with a small adjustment to the clinical protocol. Zilosul has been administered to several hundred patients across the phase 2 clinical program in Australia and the Special Access Scheme with no significant safety matters to note.

### Investment View: Maintain Buy (Spec)

We now expect the opening of the IND will be delayed until at least October 2021 and accordingly, this pushes back approval by 6 months compared to our previous expectation. First commercial revenues expected in late CY24. The timing of spend on the clinical program has been amended in the forecast to reflect the change in start date. In our view, the opening of the IND will represent a significant milestone for PAR with recruitment of clinical trials to begin shortly thereafter. Once recruitment begins it is likely there will further interest from marketing partners. Closing cash at 30 June 2021 was \$71.1m which we estimate represents maximum of 2 years working capital prior to any deal income. Valuation is lowered to \$3.00 and we maintain our Buy (Speculative) rating.

**Earnings Forecast**

June Year End	FY20	FY21e	FY22e	FY23e
Revenues	4.7	3.4	3.0	5.2
EBITDA \$m	-12.3	-34.3	-42.6	-26.4
NPAT (underlying) \$m	-12.3	-33.8	-42.1	-25.9
NPAT (reported) \$m	-12.3	-33.8	-42.1	-25.9
EPS underlying (cps)	-6.1	-14.7	-18.4	-11.3
EPS growth %	na	na	na	-39%
PER (x)	nm	nm	nm	nm
FCF yield (%)	nm	nm	nm	nm
EV/EBITDA (x)	nm	nm	nm	nm
Dividend (cps)	-	-	-	-
Franking	0%	0%	0%	0%
Yield %	0.0%	0.0%	0.0%	0.0%
ROE %	-11.4%	-45.5%	-129.1%	-373.0%

SOURCE: BELL POTTER SECURITIES ESTIMATES

# IND Edges Closer

## Key Points:

The Investigative New Drug (IND) application for Zilosul was lodged in March 2021. While the IND has not yet been opened, the pathway towards that goal is now clear with just one matter to be resolved.

During a review of the non-clinical toxicology data (toxicology data collected from rat studies) the FDA identified a marker which caused it some safety concern. This safety matter was raised with the company earlier this year in the original set of 6 questions following the first review of the dossier for the IND.

PAR responded to the original questions, however, the FDA now requires a further explanation of this one question on toxicology. The exact nature of the FDA's concern was not discussed.

The company believes it has sufficient data to respond to the FDA's questions and is highly unlikely to be required to generate further pre-clinical data. The toxicology data was prepared by the company in 2020 following a request from the FDA.

The way forward is for the company to prepare a further response to the FDA including input from a clinical expert. PAR will also modify the clinical protocol for the phase 3 trial to include an additional monitoring step during the dose escalation phase.

## TIMING

The company intends to respond to this latest question from the FDA by the end of August 2021. It is likely the FDA will take a further 30 days to respond. Assuming there are no further questions the IND may open. Our best estimate is that the IND may open by mid-October, 2021.

## LESSON LEARNT

While the IND process has been drawn out, in our view there is nothing that could have been done to abbreviate the process. No doubt COVID has slowed down all communication with the FDA and was also responsible for slowing down the preparation of the toxicology studies. Nevertheless the company is now on the cusp of a major value creating event – being the opening of the IND.

At the completion of the Phase 3 trial, the result should be a very clean data package supported by excellent safety data – both pre-clinical and clinical.

In the interim, the company intends to commence recruitment of the phase 2b dose escalation study in Australia, ahead of the IND opening in the US. Screening for patients in Australia will begin in 4Q21. PAR is unlikely to commence recruitment in Europe until the final dose escalation work is completed in the US and Australia.

Figure 1 - Changes to earnings

	2021			2022			2023		
	New	Old	% change	New	Old	% change	New	Old	% change
Revenues	3.4	3.0	13%	3.0	3.0	0%	5.2	5.2	0%
EBITDA	-34.3	-41.4	21%	-42.6	-42.6	0%	-26.4	-21.4	23%
NPAT	-33.8	-40.9	21%	-42.1	-42.1	0%	-25.9	-20.9	24%
EPS	-14.7	-17.8	21%	-18.4	-18.4	0%	-11.3	-9.1	24%

SOURCE: BELL POTTER SECURITIES

Earlier this year we had expected enrolment of the phase 2b/3 clinical program to commence in June. This is now pushed back until at least November/December 2021. There will be approximately 1,600 patients across the phase 2b/3 program inclusive of the confirmatory study being conducted in Europe.

The adjustment to earnings reflect the expected delay to commencement of revenues from product sales. FY21 revenue and costs have been adjusted to reflect our best estimate of income and costs and closing cash based on the recent quarterly cash flow statement. There are no changes to FY22 and costs are increased in FY23. The DCF valuation is risk weighted to allow for the risk associated with the phase 3 clinical program.

Following adjustment to earnings our valuation is amended to \$3.00 from \$3.15 and we maintain our Buy (speculative) rating.

# Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals is an Australia biotechnology company focused on repurposing Pentosan Polysulfate Sodium (PPS) for the treatment of Osteoarthritis (OA) in the knee. If approved the drug will have the brand name Zilosul.

The global market for a safe, effective treatment that provides superior patient outcomes compared to the standard of care is a multiple blockbuster. The recently completed phase II study produced some highly encouraging results that are worthy of further clinical trials.

In the US along the incidence of moderate to severe osteoarthritis is estimated at 30m persons. The pricing of the drug will ultimately be determined by the economic benefit associated with its use as well as the cost of other therapies. The conservative estimate is US\$2,500 per year which places the addressable market in the tens of billions of US\$.

## PROGRESS IN THE CLINIC

December 2018 - PAR announced headline results from its phase 2b randomised, double blind, placebo controlled multicentre trial, investigating subjects with Osteoarthritis and concurrent Bone Marrow Edema (BME) lesions (n=112). The trial met the clinical endpoint of change in Knee Injury and Osteoarthritis Outcome Score (KOOS) pain achieving both clinically meaningful and statistically significant results between placebo and PPS.

The headline results were followed up with strong signals of efficacy in the secondary endpoints (including KOOS function). This phase II trial was conducted at 6 sites in Australia.

## PATHWAY TO APPROVAL

The company is pursuing a 505(b)2 registration pathway in the US. PAR is now awaiting the opening of the IND in order to commence an approval study.

## ADJACENT INDICATIONS

Paradigm recently executed an Exclusive In-License Agreement for the use of iPPS in the treatment of mucopolysaccharidoses (MPS), a group of inherited lysosomal storage disorders. A key unmet medical need in this class of inherited disease is the lack of treatment of joint pain and dysfunction akin to osteoarthritis, hence the applicability of iPPS in treating these rare joint diseases. MPS is classified as an Orphan Indication/Designation in the US/EU and provides Paradigm the opportunity to serve a US\$1.4bn p.a. market that is in desperate need of new cost-effective treatments.

## KEY RISK AREAS

**Regulatory Pathway - PAR** is seeking registration for iPPS under the 505(b)2 regulatory pathway. The pathway is designed specifically for repurposed drugs including changes in dose form, strength, route of administration, formulation, dosing regimen or indication. This proposed repurposing of PPS has some rare characteristics.

- While the drug has been approved for years as an oral format and there is ample safety data, the proposed format, the dose and the indication (being OA) are all new.
- There is also the issue of the opioid crisis. PPS is a non steroid, non opioid, non addictive substance that has been shown to have a significant impact of pain levels associated with OA. It may help to reduce the accidental deaths from opioid overdose.
- PAR intends to conduct two phase 3 studies, one pivotal study of 750 subjects and a confirmatory phase 3 study of ~400 subjects.
- PAR will present a comprehensive set of safety data from the recent Phase II trial together with data from subjects treated in the compassionate use program and two phase 3 trials, thus representing a safety set of nearly 1,400 subjects. The evidence of

treatment will be established from two adequate and well controlled studies and further supported by the phases 2 data set.

**Intellectual Property**

- The company has several patents over the formulation and dosing on iPPS for the treatment of OA. The validity of these patents is highly likely to be challenged at some point, especially if the drug is a commercial success.
- The company has an exclusive supply contract with Bene Pharmaceuticals (Bene). We understand the exclusivity applies to human use only (excludes veterinary use). Bene holds the only drug Masterfile with the FDA to manufacture PPS. This supply contract represents a crucial piece of the company's value as it effectively prevents or delays the creation of generics.
- We are not aware of the contractual conditions that may lead to a termination of this contract (if any).
- We understand there are some other manufacturers of PPS, however, these products are not registered for human use and may not be referenced in any application for registration for human use. We understand the primary use of these products is veterinary.

**Clinical Risk**

- The efficacy of iPPS has not been validated in a large, multicentre, randomised, controlled clinical trial. There is no guarantee that the results from earlier studies will be repeated in a larger phase III study.

**Commercial Validation**

- Our valuation makes assumptions regarding selling price and volume in relation to future revenues from the sale of iPPS. In order for physicians to prescribe the drug and for payers to offer reimbursement, the clinical trials will need to demonstrate clinically significant improvement over the standard of care i.e. meaningful improvement in patient quality of life for pain reduction, side effect management and mobility amongst others. Early indicators based on the data from the phase II study are encouraging.

# Paradigm Biopharmaceuticals

as at 3 August 2021

Recommendation Buy, Speculative  
Price \$1.97  
Valuation \$3.00

Table 1 - Financial summary

Profit & Loss (A\$m)	FY19	FY20	FY21e	FY22e	FY23e						
<b>Year Ending June</b>						<b>Last sale 03/08/2021</b>	1.97				
<b>Gross royalties</b>	-	-	-	-	-	<b>Recommendation</b>	Buy (Spec)				
Gross milestones	-	-	-	-	-	Issued Capital	227.2				
Gross revenues	-	-	-	-	0.4	Market Cap	447.6				
Risk adjusted revenues	-	-	-	-	0.2						
COGS (Bene Royalty expense)	-	-	-	-	0	<b>Valuation Ratios (A\$m)</b>	<b>FY19</b>	<b>FY20</b>	<b>FY21e</b>	<b>FY22e</b>	<b>FY23e</b>
<b>Gross profit</b>	-	-	-	-	0	Reported EPS (cps)	-10.5	-6.1	-14.7	-18.4	-11.3
<b>GP margin</b>	na	na	na	na	na	Normalised EPS (cps)	-10.5	-6.1	-14.7	-18.4	-11.3
R&D incentive/Upfront receipts	3.2	4.7	3.4	3.0	5.0	EPS growth (%)	na	na	na	na	-39%
<b>Total revenues</b>	<b>3.2</b>	<b>4.7</b>	<b>3.4</b>	<b>3.0</b>	<b>5.2</b>	<b>PE(x)</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>
<b>Other expenses</b>	<b>-11.9</b>	<b>-17.0</b>	<b>-37.7</b>	<b>-45.6</b>	<b>-31.6</b>	<b>EV/EBITDA (x)</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>
<b>EBITDA</b>	<b>-8.7</b>	<b>-12.3</b>	<b>-34.3</b>	<b>-42.6</b>	<b>-26.4</b>	<b>EV/EBIT (x)</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>	<b>nm</b>
Depreciation	-	-	-	-	-	NTA (cps)	41.5	46.8	31.6	13.1	1.8
Amortisation	-	6.9	-	-	-	P/NTA (x)	0.0	0.0	0.1	0.2	1.1
<b>EBIT</b>	<b>-15.6</b>	<b>-12.3</b>	<b>-34.3</b>	<b>-42.6</b>	<b>-26.4</b>	Book Value (cps)	43.1	48.2	32.9	14.4	3.1
Sundry income	-	-	0.5	0.5	0.5	Price/Book (x)	0.0	0.0	0.1	0.1	0.6
Pre tax profit	-15.6	-12.3	-33.8	-42.1	-25.9	DPS (cps)	-	-	-	-	-
Tax expense	-	-	-	-	-	Payout ratio %	0%	0%	0%	0%	0%
<b>NPAT- normalised</b>	<b>-15.6</b>	<b>-12.3</b>	<b>-33.8</b>	<b>-42.1</b>	<b>-25.9</b>	Dividend Yield %	0.0%	0.0%	0.0%	0.0%	0.0%
Net abnormal items	-	-	-	-	-	Franking %	0%	0%	0%	0%	0%
<b>Reported NPAT</b>	<b>-15.6</b>	<b>-12.3</b>	<b>-33.8</b>	<b>-42.1</b>	<b>-25.9</b>	FCF yield %	-168%	-230%	-744%	-923%	-572%
<b>Cashflow (A\$m)</b>	<b>FY19</b>	<b>FY20</b>	<b>FY21e</b>	<b>FY22e</b>	<b>FY23e</b>	Net debt/Equity	0%	0%	0%	0%	0%
Gross cashflow	-6.5	-11.2	-34.1	-42.2	-26.3	Net debt/Assets	0%	0%	0%	0%	0%
Net interest	0.1	1.1	0.5	0.5	0.5	Gearing	net cash	net cash	net cash	net cash	net cash
Tax paid	0.0	0.0	0.0	0.0	0.0	Net debt/EBITDA (x)	n/a	n/a	n/a	n/a	n/a
<b>Operating cash flow</b>	<b>-6.4</b>	<b>-10.1</b>	<b>-33.6</b>	<b>-41.7</b>	<b>-25.8</b>	Interest cover (x)	n/a	n/a	n/a	n/a	n/a
Maintenance capex	0.0	-0.1	0.0	0.0	0.0						
Capitalised clinical trial spend	0.0	0.0	0.0	0.0	0.0						
<b>Free cash flow</b>	<b>-6.4</b>	<b>-10.2</b>	<b>-33.6</b>	<b>-41.7</b>	<b>-25.8</b>						
Business acquisitions	0.0	0.0	0.0	0.0	0.0						
Proceeds from issuance	82.8	34.2	0.7	0.0	0.0						
Movement in investments	0.0	0.0	0.0	0.0	0.0						
Dividends paid	0.0	0.0	0.0	0.0	0.0						
<b>Change in cash held</b>	<b>76.4</b>	<b>24.0</b>	<b>(32.9)</b>	<b>(41.7)</b>	<b>(25.8)</b>						
Cash at beginning of period	2.5	72.4	104.0	71.1	29.4						
<b>Cash at year end</b>	<b>72.4</b>	<b>104.0</b>	<b>71.1</b>	<b>29.4</b>	<b>3.6</b>						
<b>Balance Sheet (A\$m)</b>	<b>FY19</b>	<b>FY20</b>	<b>FY21e</b>	<b>FY22e</b>	<b>FY23e</b>						
Cash	72.4	104.0	71.1	29.4	3.6						
Receivables	3.5	3.5	3.4	3.0	3.0						
Other current assets	6.6	0.9	0.9	0.9	0.9						
Intangibles	-	0.1	0.1	0.1	-						
Intangibles	3.0	3.0	3.0	3.0	3.0						
Other	-	1.0	1.0	1.0	1.0						
<b>Total assets</b>	<b>85.5</b>	<b>112.4</b>	<b>79.5</b>	<b>37.4</b>	<b>11.5</b>						
Trade payables	2.3	2.8	2.8	2.8	2.8						
Other liabilities	-	0.9	0.9	1.0	1.0						
Other provisions	0.4	0.5	0.4	0.6	0.6						
<b>Total Liabilities</b>	<b>2.7</b>	<b>4.2</b>	<b>4.2</b>	<b>4.3</b>	<b>4.4</b>						
<b>Net Assets</b>	<b>82.8</b>	<b>108.2</b>	<b>75.3</b>	<b>33.0</b>	<b>7.1</b>						
Share capital	109.5	145.9	146.6	146.6	146.6						
Retained earnings	(30.7)	(41.3)	(75.1)	(117.2)	(143.1)						
Reserves	4.1	3.7	3.8	3.7	3.6						
<b>Shareholders Equity</b>	<b>82.8</b>	<b>108.2</b>	<b>75.3</b>	<b>33.0</b>	<b>7.1</b>						

SOURCE: BELL POTTER SECURITIES ESTIMATES

**Recommendation structure**

**Buy:** Expect >15% total return on a 12 month view. For stocks regarded as 'Speculative' a return of >30% is expected.

**Hold:** Expect total return between -5% and 15% on a 12 month view

**Sell:** Expect <-5% total return on a 12 month view

*Speculative Investments are either start-up enterprises with nil or only prospective operations or recently commenced operations with only forecast cash flows, or companies that have commenced operations or have been in operation for some time but have only forecast cash flows and/or a stressed balance sheet.*

*Such investments may carry an exceptionally high level of capital risk and volatility of returns.*

**Research Team**

Staff Member	Title/Sector	Phone	@bellpotter.com.au
Chris Savage	Head of Research/Industrials	612 8224 2835	csavage
<b>Analysts</b>			
TS Lim	Banks	612 8224 2810	tslim
John Hester	Healthcare	612 8224 2871	jhester
Tanushree Jain	Healthcare	612 8224 2849	tnjain
Elyse Shapiro	Healthcare	613 9235 1877	eshapiro
Steven Anastasiou	Industrials	613 9235 1952	sanastasiou
Sam Brandwood	Industrials	612 8224 2850	sbrandwood
James Filius	Industrials	613 9235 1612	jfilius
Sam Haddad	Industrials	612 8224 2819	shaddad
Alex McLean	Industrials	612 8224 2886	amclean
Hamish Murray	Industrials	613 9235 1813	hmurray
Jonathan Snape	Industrials	613 9235 1601	jsnape
David Coates	Resources	612 8224 2887	dcoates
Stuart Howe	Resources	613 9235 1856	showe
Brad Watson	Resources	618 9326 7672	bwatson
Joseph House	Resources	613 9235 1624	jhouse
<b>Associates</b>			
Olivia Hagglund	Associate Analyst	612 8224 2813	ohagglund
Michael Ardrey	Associate Analyst	613 9256 8782	mardrey

**Bell Potter Securities Limited**

ABN 25 006 390 772  
Level 29, 101 Collins Street  
Melbourne, Victoria, 3000  
Telephone +61 3 9256 8700  
[www.bellpotter.com.au](http://www.bellpotter.com.au)

**Bell Potter Securities (HK) Limited**

Room 1701, 17/F  
Prosperity Tower, 39 Queens Road  
Central, Hong Kong, 0000  
Telephone +852 3750 8400

**Bell Potter Securities (US) LLC**

Floor 39  
444 Madison Avenue, New York  
NY 10022, U.S.A  
Telephone +1 917 819 1410

**Bell Potter Securities (UK) Limited**

16 Berkeley Street  
London, England  
W1J 8DZ, United Kingdom  
Telephone +44 7734 2929

**The following may affect your legal rights. Important Disclaimer:**

This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. **In Hong Kong**, this research is being distributed by Bell Potter Securities (HK) Limited which is licensed and regulated by the Securities and Futures Commission, Hong Kong. **In the United States**, this research is issued and distributed by Bell Potter Securities (US) LLC which is a registered broker-dealer and member of FINRA. Any person receiving this report from Bell Potter Securities (US) LLC and wishing to transact in any security described herein should do so with Bell Potter Securities (US) LLC. This is general investment advice only and does not constitute personal advice to any person. Because this document has been prepared without consideration of any specific client's financial situation, particular needs and investment objectives ('relevant personal circumstances'), a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the representative of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be made aware of your relevant personal circumstances and consulted before any investment decision is made on the basis of this document. While this document is based on information from sources which are considered reliable, Bell Potter Securities Limited has not verified independently the information contained in the document and Bell Potter Securities Limited and its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility for updating any advice, views opinions, or recommendations contained in this document or for correcting any error or omission which may become apparent after the document has been issued. Except insofar as liability under any statute cannot be excluded. Bell Potter Securities Limited and its directors, employees and consultants do not accept any liability (whether arising in contract, in tort or negligence or otherwise) for any error or omission in this document or for any resulting loss or damage (whether direct, indirect, consequential or otherwise) suffered by the recipient of this document or any other person.

**Research Policies:** For Bell Potter's Research Coverage Decision Making Process and Research Independence Policy, please refer to our company website:

<https://bellpotter.com.au/research-independence-policy/>

**Disclosure of interest:** Bell Potter Securities Limited, its employees, consultants and its associates within the meaning of Chapter 7 of the Corporations Law may receive commissions, underwriting and management fees from transactions involving securities referred to in this document (which its representatives may directly share) and may from time to time hold interests in the securities referred to in this document.

**Disclosure:** Bell Potter Securities acted as lead manager of the company's 2020 capital raise for \$35m and received fees for that service.

**Biotechnology Risk Warning:**

The fact that the intellectual property base of a typical biotechnology company lies in science not generally regarded as accessible to the layman adds further to the riskiness with which biotechnology investments ought to be regarded. Clinical and regulatory risks are inherent in biotechnology stocks. Biotechnology developers usually seek US FDA approval for their technology which is a long and arduous three phase process to prove the safety, effectiveness and appropriate application or use of the developed drug and even after approval a drug can be the subject of an FDA investigation of subsequently discovered possible links between the drug and other diseases not previously diagnosed. Furthermore, the Australian exchange listed biotechnology sector is subject to influence by the global biotechnology sector, particularly that in the USA. Consequently, Australian exchange listed biotechnology stocks can experience sharp movements, both upwards and downwards, in both valuations and share prices, as a result of a re-rating of the sector both globally and in the USA, in particular. Investors are advised to be cognisant of these risks before buying such a stock.

**ANALYST CERTIFICATION:** Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.